STAT+: Regeneron’s Eylea biosimilar fight heats up
STAT
SEPTEMBER 24, 2024
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock. Regeneron filed an appeal.
Let's personalize your content